$1.13
0.00% yesterday
NYSE, Oct 17, 10:00 pm CET
ISIN
US2941001024
Symbol
ENZ
Sector
Industry

Enzo Biochem, Inc. Stock price

$1.13
+0.01 0.89% 1M
-0.02 1.74% 6M
-0.26 18.71% YTD
-0.25 18.12% 1Y
-2.18 65.86% 3Y
-2.11 65.12% 5Y
-3.72 76.70% 10Y
NYSE, Closing price Thu, Oct 17 2024
+0.00 0.00%
ISIN
US2941001024
Symbol
ENZ
Sector
Industry

Key metrics

Market capitalization $58.15m
Enterprise Value $3.25m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.05
P/S ratio (TTM) P/S ratio 0.82
P/B ratio (TTM) P/B ratio 0.84
Revenue growth (TTM) Revenue growth -36.38%
Revenue (TTM) Revenue $71.01m
EBIT (operating result TTM) EBIT $-39.97m
Free Cash Flow (TTM) Free Cash Flow $-31.57m
Cash position $62.16m
EPS (TTM) EPS $-0.93
Short interest 1.33%
Show more

Is Enzo Biochem, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,907 stocks worldwide.

Enzo Biochem, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Enzo Biochem, Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Enzo Biochem, Inc.:

Buy
100%

Financial data from Enzo Biochem, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Apr '24
+/-
%
71 71
0% 0%
100%
- Direct Costs 60 60
0% 0%
85%
11 11
0% 0%
15%
- Selling and Administrative Expenses - -
- Research and Development Expense 4.47 4.47
0% 0%
6%
-37 -37
0% 0%
-52%
- Depreciation and Amortization 2.77 2.77
0% 0%
4%
EBIT (Operating Income) EBIT -40 -40
0% 0%
-56%
Net Profit -46 -46
0% 0%
-64%

In millions USD.

Don't miss a Thing! We will send you all news about Enzo Biochem, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Enzo Biochem, Inc. Stock News

Negative
Reuters
2 months ago
Enzo Biochem will pay $4.5 million to settle claims it failed to adequately safeguard personal and private health information of its patients, New York Attorney General Letitia James said on Tuedsay.
Positive
Seeking Alpha
3 months ago
Enzo Biochem shareholders frustrated with lack of capital returns following Clinical Labs sale to Labcorp Holdings. Stock trading near historic lows, but potential for attractive returns with simplified Life Sciences division and strong CEO incentives. Valuation potential of $2.00-3.22/share with $35m net cash and $75-120m business value, pending resolution of legal issues and potential share b...
Neutral
GlobeNewsWire
4 months ago
FARMINGDALE, N.Y., June 13, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal third quarter ended April 30, 2024.
More Enzo Biochem, Inc. News

Company Profile

Enzo Biochem, Inc. engages in the development, manufacture and sale of technology solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians globally. It operates through the following segments: Enzo Clinical Laboratory Services, Enzo Life Sciences Products, and Enzo Therapeutics. The Enzo Clinical Laboratory Services segment includes clinical reference laboratory providing a wide range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. The Enzo Life Sciences Products segment manufactures, develops and markets products and tools for clinical research, drug development and bioscience research customers worldwide. The Enzo Therapeutics segment develops multiple novel approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases, many of which are derived from the pioneering work of Enzo Life Sciences. The company was founded by Elazar Rabbani, Barry W. Weiner and Shahram K. Rabbani in 1976 and is headquartered in New York, NY.

Head office United States
CEO Kara Cannon
Employees 190
Founded 1976
Website www.enzo.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today